EFG Asset Management Americas Corp. raised its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 56.9% in the 4th quarter, Holdings Channel reports. The firm owned 5,110 shares of the company’s stock after purchasing an additional 1,854 shares during the quarter. EFG Asset Management Americas Corp.’s holdings in IDEXX Laboratories were worth $799,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Zions Bancorporation acquired a new stake in shares of IDEXX Laboratories in the third quarter worth $162,000. Benjamin F. Edwards & Company Inc. increased its position in shares of IDEXX Laboratories by 1,000.0% in the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 1,100 shares of the company’s stock worth $172,000 after acquiring an additional 1,000 shares in the last quarter. SignalPoint Asset Management LLC acquired a new stake in shares of IDEXX Laboratories in the fourth quarter worth $200,000. Ledyard National Bank increased its position in shares of IDEXX Laboratories by 58.9% in the fourth quarter. Ledyard National Bank now owns 1,295 shares of the company’s stock worth $203,000 after acquiring an additional 480 shares in the last quarter. Finally, BB&T Securities LLC acquired a new stake in shares of IDEXX Laboratories in the third quarter worth $213,000. 86.50% of the stock is owned by hedge funds and other institutional investors.

In other IDEXX Laboratories news, VP Brian P. Mckeon sold 6,602 shares of the stock in a transaction on Monday, February 5th. The shares were sold at an average price of $181.36, for a total transaction of $1,197,338.72. Following the transaction, the vice president now directly owns 47,040 shares in the company, valued at approximately $8,531,174.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Jonathan W. Ayers sold 18,000 shares of the stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $153.61, for a total transaction of $2,764,980.00. Following the transaction, the chief executive officer now owns 1,064,573 shares in the company, valued at $163,529,058.53. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 104,762 shares of company stock valued at $17,967,464. Company insiders own 2.77% of the company’s stock.

Shares of IDEXX Laboratories, Inc. (IDXX) opened at $175.06 on Tuesday. The firm has a market cap of $15,084.48, a price-to-earnings ratio of 59.54, a P/E/G ratio of 2.13 and a beta of 0.58. IDEXX Laboratories, Inc. has a fifty-two week low of $140.63 and a fifty-two week high of $198.73. The company has a current ratio of 0.97, a quick ratio of 0.80 and a debt-to-equity ratio of -11.26.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Thursday, February 1st. The company reported $0.77 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.73 by $0.04. The business had revenue of $506.00 million during the quarter, compared to analyst estimates of $490.51 million. IDEXX Laboratories had a net margin of 13.36% and a negative return on equity of 432.19%. The business’s revenue was up 14.2% on a year-over-year basis. During the same period last year, the business earned $0.58 EPS. equities analysts anticipate that IDEXX Laboratories, Inc. will post 4.09 earnings per share for the current year.

Several equities research analysts have recently issued reports on the stock. BidaskClub lowered shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Friday. Zacks Investment Research raised shares of IDEXX Laboratories from a “hold” rating to a “strong-buy” rating and set a $214.00 price objective for the company in a research report on Monday, February 5th. Bank of America increased their price objective on shares of IDEXX Laboratories from $200.00 to $220.00 and gave the stock a “buy” rating in a research report on Friday, February 2nd. Piper Jaffray Companies raised their price target on shares of IDEXX Laboratories to $211.00 and gave the company an “overweight” rating in a report on Thursday, February 1st. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $210.00 price target on shares of IDEXX Laboratories in a report on Monday, January 29th. One research analyst has rated the stock with a sell rating, six have given a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $194.00.

TRADEMARK VIOLATION WARNING: This piece was published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://theolympiareport.com/2018/02/13/idexx-laboratories-inc-idxx-shares-bought-by-efg-asset-management-americas-corp.html.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.